.jpg)
.png)
All
Hormone replacement therapy (HRT) in post-menopausal women has been a topic of constant debate. HRT with conjugated equine estrogens (CEE) or conjugated equine estrogens with progesterone, was perceived not only to relieve vasomotor symptoms associated with menopause but also to protect... more
I am honored and excited to be the president of the SWLA for the next 12 months. I look forward to working with our board of directors and as many of the members in our region as possible. I submit that many of you have great ideas in how to grow our membership and move our organization... more
.session-row { background-color: #0f8e44; color: white } .programming-row { background-color: #1a1f1b; color: white } .education-row { background-color: #cddc28; color: black; } table tr td:nth-child(1... more
Regeneron Pharmaceuticals, Inc. today announced that the New England Journal of Medicine (NEJM) published positive results from the Phase 3 trial of evinacumab in 65 patients with homozygous familial hypercholesterolemia (HoFH). Evinacumab is an investigational medicine that... more
.webform-client-form { display: none; } Celebrating leadership, achievement, and the future of lipid care. Saturday, June 13, 2026 6:30–7:45 PM CT Sheraton Grand Chicago Riverwalk NLA Scientific Sessions Host Hotel | Chicago, IL Gather with your fellow attendees at the 2026 #... more
Cardiovascular disease (CVD) remains the leading cause of death for women in the United States.(1) Unique factors affecting a woman’s health contribute significantly to CVD risk, but historically were not always represented in major guidelines. Some of these factors include hormonal changes, the... more
Happy New Year from the Foundation of the National Lipid Association! We are hard at work ensuring that 2016 is as much of a success as 2015. Part of that success stems from the many fundraising events sponsored by the Foundation. We are pleased to announce the first Foundation event of the year... more
Although statin therapy is a cornerstone of cardiovascular disease prevention, and although it achieves the largest reduction of low-density lipoprotein (LDLC), 1 and has one of the safest overall side-effect profiles among lipid-lowering medications, some patients are unable to tolerate statins... more
.field-name-field-pagetitle-banner img { max-width: 100%; margin: 0 auto; }